We are transforming genetic testing

Genetic disorders are caused by a wide variety of DNA changes that, until now, have required different technologies to detect. Traditional methodologies biochemically extract a slice of the DNA and then sequence it. This approach has produced a vast number of different tests that are designed to detect specific DNA changes within certain limitations.  Identifying the right test for the patient is often challenging. Further complicated by limited sensitivity and specificity, this leads to missed or delayed diagnoses and increased residual risk.

Our whole genome sequence (WGS) based methodology is shifting the genetic testing paradigm, overcoming the limitations of traditional technologies. We sequence the entire DNA and then slice the data in any number of relevant ways for analysis. With its ability to detect all major types of genetic variation, our Genomic Unity® testing methodology provides a better test at a lower overall cost to patients and payors.

Our interdisciplinary team of talented medical professionals, bioinformaticians, software engineers, information technology and operations professionals are leading the way to better genetic testing, one patient at a time


VP Market Access and Reimbursement


Haim Neerman

Haim’s career spans over 20 years of technology entrepreneurship. Prior to co-founding Variantyx, Haim co-founded Credorax Inc. – a global credit card acquiring bank, Fabrix systems (acquired by Ericson), Bandwiz Inc. and Actil Ltd.

Haim is a physics, math and computer science graduate of the Talpiot program / Hebrew University of Jerusalem.

Noam Shomron, PhD

Professor Noam Shomron heads the Genomic Intelligence Research Laboratory at the Faculty of Medicine at Tel Aviv University. Professor Shomron leads a multidisciplinary team of scientists consisting of biologists, physicians, engineers, bioinformaticians and mathematicians. His team aims to deepen our understanding of disease etiology in order to generate a significant impact through translating ideas into clinical reality.

Professor Shomron is also the Director of the Djerassi Institute of Oncology; Director of Rare Genomics Israel a non-profit organization that assists children and families with undiagnosed genetic disorders; Academic Director of ScienceAbroad; Editor of “Deep Sequencing Data Analysis” Springer Production book, Edition I/II and co-founder of several Biotech companies.

Muthu Meyyappan, PhD

Muthu serves as the Chief Commercial Officer and is responsible for the overall commercial strategy including sales, marketing and customer support. His primary focus is to drive market adoption of Variantyx’s products and services and to drive revenue growth. Prior to joining Variantyx, Muthu was the Vice President of Advanced Genomics Commercial Operations for QIAGEN where he was responsible for worldwide revenue for the bioinformatics franchise. He has more than 20+ years’ experience in customer facing environments within the pharmaceutical, biotech, academic research and clinical sectors where he represented Incyte Genomics and was the Chief Business Officer for BIOBASE Corporation.

Muthu holds a Bachelor’s degree in Biotechnology from the Rochester Institute of Technology, New York and a PhD in Cancer Biology from the Southern Alberta Cancer Research Center, in Calgary, Canada.

Christine Stanley PhD, FACMG
Chief Director Clinical Genomics

As Variantyx’s Chief Director of Clinical Genomics, Christine is responsible for overseeing clinical genomic interpretations and regulatory compliance for the clinical laboratory. Prior to joining Variantyx, Christine held positions as Head of Clinical Laboratory at WuXi NextCODE, Chief Director of Clinical Genomics at Courtagen Life Sciences and Genetics Director at Athena Diagnostics. She maintains a part-time appointment as Clinical Laboratory Director of QnA Diagnostics.

Christine holds a Bachelor’s degree in Genetics from Texas A&M University and a PhD in Human Genetics from the Medical College of Virginia with fellowship training at Boston University in clinical molecular genetics. She is a diplomate of the American Board of Medical Genetics and Genomics and a Fellow of the American College of Medical Genetics and Genomics.

Tomer Jackman

Tomer serves as the Chief Operating Officer of Variantyx and is responsible for delivering services to customers. Prior to co-founding Variantyx, Tomer was responsible for hardware development operations in the Pivotal/Greenplum division of EMC2 where he helped develop server clusters for “Massive Parallel Processing” databases. This followed a decade with EMC2 in several hardware engineering roles and work in R&D with HP/Indigo.

Tomer holds a high-tech MBA from Northeastern University in Boston, and a BSc in Electrical Engineering from Tel-Aviv University.

Yaron Rachmany

Yaron Rachmany oversees Variantyx’ IT systems and business processes. Prior to joining Variantyx, Yaron served as Director of Systems Operations and as a Director of IT Applications at Semtech Corporation (NASDAQ: SMTC). Prior to Semtech Yaron held the VP of Information Systems position with Credorax. Prior to Credorax, Yaron held senior Information Systems positions with Microsemi (NASDAQ: MSCC), Intel (NASDAQ: INTC) and ECI Telecom.

Yaron holds an M.Sc. and a B.Sc. in Industrial Engineering and Management (specialized in Information Systems) from Ben Gurion University in Israel.

Daryl Spinner, PhD
VP Market Access and Reimbursement

As Variantyx’s Vice President of Market Access and Reimbursement, Daryl is responsible for working with payors to expand patient access to clinically relevant genetic testing. Prior to joining Variantyx, Daryl held positions as Managing Director of Strategy at Evidera and Senior Director of Managed Care and Reimbursement at Courtagen Life Sciences.

Daryl holds a Bachelor’s degree in Chemistry and a PhD in Molecular and Cellular Pharmacology from the State University of New York at Stony Brook and an MBA from Duke University.

Jennifer Hogan, PhD
VP Marketing

Jennifer serves as the VP of Marketing and is responsible for content strategy and tactical execution driving awareness, education and lead generation for Variantyx’s products and services. Prior to joining Variantyx, Jennifer led product management and product marketing for the genetic disease portfolio within QIAGEN’s bioinformatics business area. She has many years of experience leading customer-focused product development of biological databases and software at QIAGEN, BIOBASE Corporation and Incyte Genomics.

Jennifer holds a Bachelor’s degree in Biology from the University of Michigan, Flint and received her PhD in Biochemistry and Molecular Biology from the University of New Hampshire.